Loading...

Purified anti-mouse Ly-6C Antibody

Pricing & Availability
Clone
HK1.4 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus C
Isotype
Rat IgG2c, κ
Ave. Rating
Submit a Review
Product Citations
publications
HK1dot4_Pure_070808.jpg
C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_070808.jpg
    C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_Ly6c_Antibody_2_102518
    Fresh, frozen mouse spleen was stained with purified Ly6C clone HK1.4 conjugated and detected with a Cy5 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Save
128001 50 µg ¥14,300
128002 500 µg ¥51,700
Description

Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
L3 cloned CTL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C58.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.

Application References

(PubMed link indicates BioLegend citation)
  1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
  2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
  3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
  4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
  5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
  6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
  7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
Product Citations
  1. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  2. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  3. Filippini D, et al. 2019. Sci Rep. 9:12286. PubMed
  4. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  5. Nobs SP, et al. 2021. J Allergy Clin Immunol. . PubMed
  6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  7. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  8. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  9. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  10. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  11. Orecchioni M, et al. 2022. Methods Mol Biol. 2419:779. PubMed
  12. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  13. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  14. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  15. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  16. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  17. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  18. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  19. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  20. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  21. Hofstee MI, et al. 2021. Eur Cell Mater. 41:774. PubMed
  22. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  23. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  24. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  25. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  26. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  27. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  28. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  29. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  30. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  31. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  32. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  33. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  34. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  35. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  36. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  37. Majer O, et al. 2019. Nature. 575:366. PubMed
  38. Blriot C, et al. 2021. Immunity. :. PubMed
  39. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  40. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  41. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  42. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  43. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  44. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  45. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  46. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  47. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  48. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  49. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  50. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  51. Watson N, et al. 2015. J Immunol. 194:2796. PubMed
  52. Rogers P, Driessnack M, and Schwartz E. 2017. PLoS One. 10.1371/journal.pone.0181985. PubMed
  53. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  54. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  55. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  56. Zhang C, et al. 2020. Hear Res. 393:107996. PubMed
  57. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  58. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  59. Hofstee MI, et al. 2021. Pathogens. 10:. PubMed
  60. Jones GS, et al. 2020. mSphere. 5:. PubMed
  61. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  62. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  63. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  64. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  65. De Alessandris S, et al. 2019. J Leukoc Biol. 105:1183. PubMed
  66. Wichaiyo S, et al. 2019. Haematologica. 104:1648. PubMed
RRID
AB_1134213 (BioLegend Cat. No. 128001)
AB_1134214 (BioLegend Cat. No. 128002)

Antigen Details

Structure
14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.

Cell Type
Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID
17067 View all products for this Gene ID
UniProt
View information about Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 10/25/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account